GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

This copy is for your personal, non-commercial use only ... the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

European shares ended lower on Wednesday, following a broad rally earlier in the session, hurt by a drop in utilities shares ...

Novo Nordisk's blockbuster Wegovy weight-loss drug beat sales expectations ... will assume responsibility for the company's commercial operation in the U.S. while staying in charge of global ...

Novo Nordisk will be responsible for these early development costs, clinical development, regulatory, commercial manufacturing, and commercialization. “The agreement with Novo Nordisk reflects ...

If your insurance provider covers Wegovy, you might be able to save up to $225 a month, so your out-of-pocket cost could be reduced to zero. For Rybelsus, if you’re eligible and your commercial ...